Experts believe erectile dysfunction drug Aviptadil could outpace Covid-19

Drugs used for erectile dysfunction have the potential to treat severely ill Covid-19 patients, scientists say.

Aviptadil — branded Invicorp in the UK but not yet marketed in the US — is moving to the next stage of clinical trials after promising results.

Almost 300 patients with moderate to severe seizures Coronavirus Inhaled medications are given at five US hospitals.

The drug manufacturers claim that 16 patients in the United States removed their ventilators or recovered from respiratory failure within four days of inhaling the drug.

And doctors in Houston claim that the drug helped one patient on the verge of death make a “rapid recovery.”

The drug, a synthetic form of a natural peptide in the body called VIP, protects lung cells from damage by reducing inflammation.

Brazilian researchers have also shown that the peptide can prevent coronaviruses from entering cells and replicating.

Apoptadil is designated Invicorp in the UK as an impotence treatment and is being rapidly tracked for Covid-19 clinical trials in the US after promising signs

Aviptadil is combined with another ingredient called phentolamine for the treatment of erectile dysfunction.

Taking the two drugs together promotes blood flow in and out of the penis, keeping the pen firm.

The formulation is injected directly into the tissues on the sides of the penis, causing an erection after approximately 5 minutes.

Men can only get it on a prescription, and when the nurse shows them how to perform the injection, they can do it themselves.

When the Covid-19 pandemic struck, Israeli US company NeuroRx Inc developed the drug in partnership with Swiss pharmaceutical company Relief.

The companies said they were given permission to advance the trial of aviptadil to prevent respiratory failure in Covid-19 patients.

The first part of the Phase 2 and Phase 3 trials, which are scheduled to begin before September, include severe Covid-19 patients in hospital.

If the results are promising, the trial will be extended to home patients with mild to moderate Covid-19 to prevent the need for hospitalization.

Aviptadil is inhaled because the drug can reach deep inside the lung tissue.

Half of the patients will receive aviptadil, and the other half will receive a randomly selected placebo and “maximum intensive care”.

Aviptadil is already in clinical trials for ARDS — a life-threatening lung disease and a known complication of Covid-19.

According to the rescue, 7 out of 8 patients with severe ventilator ARDS have dramatically improved with VIP administration.

A doctor at the Houston Methodist Hospital said on August 1 that the drug would help “quick recovery” in patients, details were reported on the website. Preprint..

The patient developed Covid-19 while being treated for double lung transplant rejection. He removed the ventilator within 4 days.

Similar results were seen in more than 15 patients treated under emergency use, Relief and NeuroRx reported.

X-rays showed that they had a rapid improvement in blood oxygen and that the lungs were again working to pump oxygen around the body.

However, only a small number of people were treated with aviptadil, and the drug was not compared to the dummy drug, so it cannot be asserted that aviptadil actually improved patient outcomes or was a coincidence.

A placebo-controlled trial of five US hospitals demonstrates whether the aviptadil actually treats patients.

About 70% of VIP in the body is associated with specific cells in the lung called alveolar type 2 cells.

These cells are important for the transmission of oxygen to the body and without them respiratory failure occurs.

Cells are coated with the ACE-2 receptor, which acts as an entrance for the virus to replicate, making it a target for coronaviruses.

The theory is that synthetic VIP binds to lung cells and blocks SARS-CoV-2, which causes Covid-19, to do the same.

Researchers at the Oswald Cruz Institute in Rio de Janeiro have discovered that aviptadil inhibits viral replication in human lung cells in laboratory conditions.

The same expert Preprinted paperIt also states that survivors connected to the ventilator had more VIP in their blood than those who died.

NeuroRx CEO Jonathan Javitt said: “No other antiviral agent has demonstrated rapid recovery from viral infections and laboratory inhibition of viral replication.”

VIP has been shown to have anti-inflammatory effects in animals. Inflammation is a known complication of Covid-19 with fatal consequences.

VIP prevents the production of inflammatory cytokines—Inflammatory cytokines can cause lung damage at high levels.

Cytokines are proteins in the body that give signals between cells. They play an important role in the normal immune response.

When the body releases many proinflammatory cytokines at one time, it is called a “cytokine storm.”

It is believed to be the major factor behind lung damage, catastrophic organ failure and death in some patients with coronavirus.

Only two drugs, lemdecivir and dexamethasone, have been shown to reduce the risk of death in patients already in hospital.

Dexamethasone Saves Up to 35% of Covid-19 Patients Reliant on Ventilation-The Most Dangerous Illness Presented by Researchers Leading Oxford University.

Remdesivir, an drug originally designed to treat Ebola hemorrhagic fever, has already been approved for treating Covid-19 patients in the UK since May.

However, remdesibir test results are less conclusive than dexamethasone.